APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Acute Ischemic Stroke Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Acute Ischemic Stroke Drugs Market Outlook and Growth Opportunities 2026

Report ID 173960300422 December 2025195 pages

Choose your research edition.

Industry ResearchAcute Ischemic Stroke Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Ischemic Stroke Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Acute Ischemic Stroke Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Ischemic Stroke Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Ischemic Stroke Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Acute Ischemic Stroke Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Acute Ischemic Stroke Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Ischemic Stroke Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Ischemic Stroke Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Acute Ischemic Stroke Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Acute Ischemic Stroke Drugs market include Sanofi, Johnson＆Johnson, Roche, Pfizer, Biogen, Bayer, AstraZeneca, ZZ Biotech and SanBio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Acute Ischemic Stroke Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Ischemic Stroke Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Ischemic Stroke Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Acute Ischemic Stroke Drugs market.

Acute Ischemic Stroke Drugs Segment by Company

Sanofi

Johnson＆Johnson

Roche

Pfizer

Biogen

Bayer

AstraZeneca

ZZ Biotech

SanBio

NoNO Inc

Daiichi Sankyo

Bristol-Myers Squibb

Boehringer Ingelheim

Athersys

Acute Ischemic Stroke Drugs Segment by Type

Tablet

Capsule

Other

Acute Ischemic Stroke Drugs Segment by Application

Hospitals

Diagnostic Centers

Others

Acute Ischemic Stroke Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Acute Ischemic Stroke Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Acute Ischemic Stroke Drugs key companies, revenue, market share, and recent developments.

3. To split the Acute Ischemic Stroke Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Acute Ischemic Stroke Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acute Ischemic Stroke Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Acute Ischemic Stroke Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Ischemic Stroke Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Ischemic Stroke Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Ischemic Stroke Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Ischemic Stroke Drugs industry.

Chapter 3: Detailed analysis of Acute Ischemic Stroke Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Acute Ischemic Stroke Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Acute Ischemic Stroke Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acute Ischemic Stroke Drugs Industry Trends Table 2. Acute Ischemic Stroke Drugs Industry Drivers Table 3. Acute Ischemic Stroke Drugs Industry Opportunities and Challenges Table 4. Acute Ischemic Stroke Drugs Industry Restraints Table 5. Global Acute Ischemic Stroke Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acute Ischemic Stroke Drugs Revenue Share by Company (2021-2026) Table 7. Global Acute Ischemic Stroke Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Acute Ischemic Stroke Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Acute Ischemic Stroke Drugs Company, Product Type & Application Table 10. Global Acute Ischemic Stroke Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Acute Ischemic Stroke Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tablet Table 15. Significant Companies of Capsule Table 16. Significant Companies of Other Table 17. Global Acute Ischemic Stroke Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Acute Ischemic Stroke Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Acute Ischemic Stroke Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Acute Ischemic Stroke Drugs Sales Value Share by Type (2021-2026) Table 21. Global Acute Ischemic Stroke Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Diagnostic Centers Table 24. Significant Companies of Others Table 25. Global Acute Ischemic Stroke Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Acute Ischemic Stroke Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Acute Ischemic Stroke Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Acute Ischemic Stroke Drugs Sales Value Share by Application (2021-2026) Table 29. Global Acute Ischemic Stroke Drugs Sales Value Share by Application (2027-2032) Table 30. Global Acute Ischemic Stroke Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Acute Ischemic Stroke Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Acute Ischemic Stroke Drugs Sales Value Share by Region (2021-2026) Table 33. Global Acute Ischemic Stroke Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Acute Ischemic Stroke Drugs Sales Value Share by Region (2027-2032) Table 35. Global Acute Ischemic Stroke Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Acute Ischemic Stroke Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Acute Ischemic Stroke Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Acute Ischemic Stroke Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Acute Ischemic Stroke Drugs Sales Value Market Share by Country (2027-2032) Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sanofi Acute Ischemic Stroke Drugs Product Portfolio Table 44. Sanofi Recent Development Table 45. Johnson＆Johnson Company Information Table 46. Johnson＆Johnson Business Overview Table 47. Johnson＆Johnson Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Johnson＆Johnson Acute Ischemic Stroke Drugs Product Portfolio Table 49. Johnson＆Johnson Recent Development Table 50. Roche Company Information Table 51. Roche Business Overview Table 52. Roche Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Roche Acute Ischemic Stroke Drugs Product Portfolio Table 54. Roche Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer Acute Ischemic Stroke Drugs Product Portfolio Table 59. Pfizer Recent Development Table 60. Biogen Company Information Table 61. Biogen Business Overview Table 62. Biogen Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Biogen Acute Ischemic Stroke Drugs Product Portfolio Table 64. Biogen Recent Development Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bayer Acute Ischemic Stroke Drugs Product Portfolio Table 69. Bayer Recent Development Table 70. AstraZeneca Company Information Table 71. AstraZeneca Business Overview Table 72. AstraZeneca Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. AstraZeneca Acute Ischemic Stroke Drugs Product Portfolio Table 74. AstraZeneca Recent Development Table 75. ZZ Biotech Company Information Table 76. ZZ Biotech Business Overview Table 77. ZZ Biotech Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. ZZ Biotech Acute Ischemic Stroke Drugs Product Portfolio Table 79. ZZ Biotech Recent Development Table 80. SanBio Company Information Table 81. SanBio Business Overview Table 82. SanBio Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. SanBio Acute Ischemic Stroke Drugs Product Portfolio Table 84. SanBio Recent Development Table 85. NoNO Inc Company Information Table 86. NoNO Inc Business Overview Table 87. NoNO Inc Acute Ischemic Stroke Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. NoNO Inc Acute Ischemic Stroke Drugs Product Portfolio Table 89. NoNO Inc Recent Development Table 90. Daiichi Sankyo Company Information Table 91. Daiichi Sankyo Business Overview Table 92. Daiichi Sankyo Acute Ischemic Stroke Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Daiichi Sankyo Acute Ischemic Stroke Drugs Product Portfolio Table 94. Daiichi Sankyo Recent Development Table 95. Bristol-Myers Squibb Company Information Table 96. Bristol-Myers Squibb Business Overview Table 97. Bristol-Myers Squibb Acute Ischemic Stroke Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Bristol-Myers Squibb Acute Ischemic Stroke Drugs Product Portfolio Table 99. Bristol-Myers Squibb Recent Development Table 100. Boehringer Ingelheim Company Information Table 101. Boehringer Ingelheim Business Overview Table 102. Boehringer Ingelheim Acute Ischemic Stroke Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Boehringer Ingelheim Acute Ischemic Stroke Drugs Product Portfolio Table 104. Boehringer Ingelheim Recent Development Table 105. Athersys Company Information Table 106. Athersys Business Overview Table 107. Athersys Acute Ischemic Stroke Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Athersys Acute Ischemic Stroke Drugs Product Portfolio Table 109. Athersys Recent Development Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Acute Ischemic Stroke Drugs Product Image Figure 2. Global Acute Ischemic Stroke Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Ischemic Stroke Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Acute Ischemic Stroke Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tablet Image Figure 8. Capsule Image Figure 9. Other Image Figure 10. Global Acute Ischemic Stroke Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Acute Ischemic Stroke Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Acute Ischemic Stroke Drugs Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Diagnostic Centers Image Figure 15. Others Image Figure 16. Global Acute Ischemic Stroke Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Acute Ischemic Stroke Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Acute Ischemic Stroke Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Acute Ischemic Stroke Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Acute Ischemic Stroke Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Acute Ischemic Stroke Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Acute Ischemic Stroke Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Acute Ischemic Stroke Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Acute Ischemic Stroke Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Acute Ischemic Stroke Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Acute Ischemic Stroke Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Acute Ischemic Stroke Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Acute Ischemic Stroke Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Acute Ischemic Stroke Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Acute Ischemic Stroke Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Capsule
  • Other
Applications
  • Hospitals
  • Diagnostic Centers
  • Others
Companies covered
  • Sanofi
  • Johnson＆Johnson
  • Roche
  • Pfizer
  • Biogen
  • Bayer
  • AstraZeneca
  • ZZ Biotech
  • SanBio
  • NoNO Inc
  • Daiichi Sankyo
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Athersys

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Acute Ischemic Stroke Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Acute Ischemic Stroke Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Acute Ischemic Stroke Drugs Market Dynamics
  1. 2.1 Acute Ischemic Stroke Drugs Industry Trends
  2. 2.2 Acute Ischemic Stroke Drugs Industry Drivers
  3. 2.3 Acute Ischemic Stroke Drugs Industry Opportunities and Challenges
  4. 2.4 Acute Ischemic Stroke Drugs Industry Restraints
3 Acute Ischemic Stroke Drugs Market by Company
  1. 3.1 Global Acute Ischemic Stroke Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Acute Ischemic Stroke Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Acute Ischemic Stroke Drugs Company Ranking (2024-2026)
  4. 3.4 Global Acute Ischemic Stroke Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Acute Ischemic Stroke Drugs Company Product Type and Application
  6. 3.6 Global Acute Ischemic Stroke Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Acute Ischemic Stroke Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Acute Ischemic Stroke Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Acute Ischemic Stroke Drugs Market by Type
  1. 4.1 Acute Ischemic Stroke Drugs Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Capsule
  4. 4.1.3 Other
  5. 4.2 Global Acute Ischemic Stroke Drugs Sales Value by Type
  6. 4.2.1 Global Acute Ischemic Stroke Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Acute Ischemic Stroke Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Acute Ischemic Stroke Drugs Sales Value Share by Type (2021-2032)
5 Acute Ischemic Stroke Drugs Market by Application
  1. 5.1 Acute Ischemic Stroke Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Diagnostic Centers
  4. 5.1.3 Others
  5. 5.2 Global Acute Ischemic Stroke Drugs Sales Value by Application
  6. 5.2.1 Global Acute Ischemic Stroke Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Acute Ischemic Stroke Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Acute Ischemic Stroke Drugs Sales Value Share by Application (2021-2032)
6 Acute Ischemic Stroke Drugs Regional Value Analysis
  1. 6.1 Global Acute Ischemic Stroke Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Ischemic Stroke Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Acute Ischemic Stroke Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Acute Ischemic Stroke Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Acute Ischemic Stroke Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Acute Ischemic Stroke Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Acute Ischemic Stroke Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Acute Ischemic Stroke Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Acute Ischemic Stroke Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Acute Ischemic Stroke Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Acute Ischemic Stroke Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Acute Ischemic Stroke Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Acute Ischemic Stroke Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Acute Ischemic Stroke Drugs Sales Value Share by Country, 2025 VS 2032
7 Acute Ischemic Stroke Drugs Country-level Value Analysis
  1. 7.1 Global Acute Ischemic Stroke Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acute Ischemic Stroke Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Acute Ischemic Stroke Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Acute Ischemic Stroke Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Acute Ischemic Stroke Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Acute Ischemic Stroke Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Acute Ischemic Stroke Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Acute Ischemic Stroke Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson＆Johnson
  8. 8.2.1 Johnson＆Johnson Company Information
  9. 8.2.2 Johnson＆Johnson Business Overview
  10. 8.2.3 Johnson＆Johnson Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson＆Johnson Acute Ischemic Stroke Drugs Product Portfolio
  12. 8.2.5 Johnson＆Johnson Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Acute Ischemic Stroke Drugs Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Acute Ischemic Stroke Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Biogen
  26. 8.5.1 Biogen Company Information
  27. 8.5.2 Biogen Business Overview
  28. 8.5.3 Biogen Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biogen Acute Ischemic Stroke Drugs Product Portfolio
  30. 8.5.5 Biogen Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Acute Ischemic Stroke Drugs Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Acute Ischemic Stroke Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 ZZ Biotech
  44. 8.8.1 ZZ Biotech Company Information
  45. 8.8.2 ZZ Biotech Business Overview
  46. 8.8.3 ZZ Biotech Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ZZ Biotech Acute Ischemic Stroke Drugs Product Portfolio
  48. 8.8.5 ZZ Biotech Recent Developments
  49. 8.9 SanBio
  50. 8.9.1 SanBio Company Information
  51. 8.9.2 SanBio Business Overview
  52. 8.9.3 SanBio Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 SanBio Acute Ischemic Stroke Drugs Product Portfolio
  54. 8.9.5 SanBio Recent Developments
  55. 8.10 NoNO Inc
  56. 8.10.1 NoNO Inc Company Information
  57. 8.10.2 NoNO Inc Business Overview
  58. 8.10.3 NoNO Inc Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 NoNO Inc Acute Ischemic Stroke Drugs Product Portfolio
  60. 8.10.5 NoNO Inc Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Acute Ischemic Stroke Drugs Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 Bristol-Myers Squibb
  68. 8.12.1 Bristol-Myers Squibb Company Information
  69. 8.12.2 Bristol-Myers Squibb Business Overview
  70. 8.12.3 Bristol-Myers Squibb Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb Acute Ischemic Stroke Drugs Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Recent Developments
  73. 8.13 Boehringer Ingelheim
  74. 8.13.1 Boehringer Ingelheim Company Information
  75. 8.13.2 Boehringer Ingelheim Business Overview
  76. 8.13.3 Boehringer Ingelheim Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Boehringer Ingelheim Acute Ischemic Stroke Drugs Product Portfolio
  78. 8.13.5 Boehringer Ingelheim Recent Developments
  79. 8.14 Athersys
  80. 8.14.1 Athersys Company Information
  81. 8.14.2 Athersys Business Overview
  82. 8.14.3 Athersys Acute Ischemic Stroke Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Athersys Acute Ischemic Stroke Drugs Product Portfolio
  84. 8.14.5 Athersys Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst